Mental Health

Wisconsin’s First Dedicated Emergency Mental Health Facility Opens in La Crosse
Emplify Health by Gundersen opens EmPATH, the state’s first emergency mental health facility, providing dedicated crisis care within 23 hours.

Gillian Ragan Foundation to Host First Community Fundraiser at Pinnacle Brewing Company
The Gillian Ragan Foundation, supporting families who lost a child, will hold its inaugural fundraiser on May 17, 2026, featuring a hybrid silent auction to fund mental health therapy and grief counseling.

Helus Pharma Corrects TARA Mind Partnership Announcement, Reaffirms Alignment with Executive Order on Mental Health
Helus Pharma issued a correction to its partnership announcement with TARA Mind, removing references to Veterans Exploring Treatment Solutions while reaffirming the collaboration's support for Phase 3 recruitment in major depressive disorder and alignment with a recent executive order on mental health treatments.

Helus Pharma Partners with TARA Mind to Boost Veteran Recruitment in Phase 3 Depression Trial
Helus Pharma collaborates with TARA Mind and VETS to recruit veterans for its Phase 3 trial of HLP003 for major depressive disorder, aligning with a recent executive order on mental health.

Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.

Loneliness Identified as Risk Factor for Degenerative Heart Valve Disease
New research reveals that loneliness, distinct from social isolation, is associated with a significantly higher risk of developing degenerative heart valve disease, suggesting it could be a modifiable risk factor with important implications for prevention and treatment strategies.

NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.

MindBio Therapeutics Expands AI Intoxication Detection with New Data Collection Platform
MindBio Therapeutics has launched Intox Collect™, broadening its AI-driven intoxication detection capabilities beyond alcohol to include multiple central nervous system stimulants and depressants, with implications for workplace safety across high-risk industries.

New Book Addresses Mental Health Crisis Through Faith-Based Approach
Dr. Walter Malone Jr.'s new book 'Tailored to Win' offers biblical solutions to rising anxiety and depression rates, providing practical guidance for finding purpose and spiritual strength.

Cybin Reports Strong Q2 2025 Results and Advances Late-Stage Neuropsychiatry Programs
Cybin Inc. has reported strong institutional demand in its second-quarter 2025 results while advancing multiple late-stage clinical programs for mental health treatments, positioning the company for key 2026 data readouts that could significantly impact neuropsychiatry treatment options.

Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.

Former NASA Engineer Releases Book on Anxiety Relief Through Energy Therapy
Mark L. Fox, former Space Shuttle Chief Engineer, has published a book promoting PEMF therapy as a drug-free solution for anxiety, chronic pain, and sleep disorders based on two decades of research.

CDC Data Debunks Holiday Suicide Myth as International Survivors Day Highlights Need for Accurate Information
New analysis reveals suicide rates are actually lowest in December, challenging persistent media narratives about holiday suicide spikes while raising concerns about antidepressant usage and suicide prevention effectiveness.

HOPE Therapeutics Launches Revolutionary One-Day Depression Treatment Protocol in Florida
NRx Pharmaceuticals' subsidiary HOPE Therapeutics has initiated Florida's first deployment of a rapid one-day TMS protocol for treatment-resistant depression, potentially transforming care for millions suffering from depression and PTSD.

Dogtopia Foundation Marks Veterans Day with $5 Million in Service Dog Support for Veterans
The Dogtopia Foundation has raised over $5 million to fund service dogs for more than 700 veteran teams nationwide, highlighting the measurable benefits these companions provide for veterans with PTSD.

Author Matthew Adcock Releases Spiritual Guide 'The Treasure Within' to Help Readers Find Purpose and Peace
Matthew Adcock's debut book 'The Treasure Within' offers Christian readers a spiritual journey to discover purpose and identity through biblical teachings, providing guidance for those struggling with anxiety, depression, or seeking direction.

Sgt. Bo Named Winner of 15th Annual American Humane Hero Dog Awards
Sgt. Bo, a therapy dog who provided crucial emotional support to Nashville students after the Covenant School shooting, has been honored as the 2025 American Humane Hero Dog, highlighting the vital role animals play in community healing and crisis response.

Fifth Annual Sickle Cell Caregiver Summit Focuses on Mental Wellness and Advocacy
The upcoming virtual Sickle Cell Caregiver Summit brings global attention to the critical role of caregivers in managing sickle cell disease while addressing mental health challenges and building advocacy skills.

Cybin Inc. Announces Q2 2025 Financial Results and Business Update Conference Call
Cybin Inc. will host a conference call on November 13, 2025, to discuss its second-quarter financial results and provide updates on its late-stage neuropsychiatry pipeline, including breakthrough-designated psychedelic treatments for major depressive disorder and generalized anxiety disorder.

Shifa Therapy Partners with Mosques and Community Centers to Expand Mental Health Access
Shifa Therapy's partnership with mosques and community centers aims to make culturally sensitive mental health support more accessible to Muslim communities by integrating therapy services into familiar faith-based settings.

Cybin Inc. to Present at Guggenheim Healthcare Innovation Conference Amid Phase 3 Mental Health Drug Development
Cybin Inc. announced its participation in the Guggenheim Healthcare Innovation Conference as the company advances its Phase 3 clinical trials for novel mental health treatments, highlighting growing investor interest in innovative neuropsychiatry solutions.

Austin Chiropractor Prescribes 'Time Out Rx' as Antidote to Modern Burnout Culture
An Austin chiropractor's prescription for strategic pauses addresses the growing epidemic of burnout by focusing on nervous system restoration rather than productivity hacks.

Cybin Secures $175 Million in Funding to Advance Mental Health Therapeutics
Cybin Inc. has closed a $175 million registered direct offering with top healthcare investors, providing critical capital to advance its Phase 3 clinical programs for novel mental health treatments addressing major depressive disorder and generalized anxiety disorder.

Cybin Chief Medical Officer to Present at Prestigious 2025 Milken Institute Health Summit
Cybin Inc.'s Chief Medical Officer will participate in the 2025 Milken Institute Future of Health Summit, highlighting the company's advanced clinical-stage mental health treatments and their potential to address significant unmet medical needs.

Cybin Secures $175 Million in Registered Direct Offering to Advance Mental Health Treatments
Cybin Inc. has raised $175 million through a registered direct offering, providing crucial funding to advance its late-stage clinical trials for novel mental health treatments including CYB003 for major depressive disorder and CYB004 for generalized anxiety disorder.

Raina Shephard's New Book Offers Spiritual Healing Framework for Trauma Survivors
Raina Shephard's 'Angels, Healing & Purpose' provides practical spiritual tools for trauma recovery, transforming personal suffering into purpose through divine guidance and healing practices.

Spiritual Mentor Raina Shephard Releases Trauma Healing Guide Combining Personal Journey with Practical Exercises
Author Raina Shephard's new book 'Angels, Healing & Purpose' offers a comprehensive approach to emotional and spiritual recovery from trauma through memoir, workbook exercises, and spiritual practices.

180 Turning Lives Around Receives $20,000 Grant to Support Domestic Violence Survivors
A $20,000 grant from the Mary Kay Ash Foundation will help sustain emergency shelter services for domestic violence survivors in Monmouth County, supporting critical safety and recovery programs.

New Book Offers Faith-Based Approach to Mental Health Challenges
Certified Life Coach Miss Walker's new book 'The Secret Formula of Amazing Hope' provides a structured three-step approach combining biblical principles with life coaching techniques to help individuals navigate stress, anxiety, and depression.

Dr. Azfar Malik Grant Opens 2026 Applications for Healthcare Students Emphasizing Mental Health
The Dr. Azfar Malik Grant for Healthcare Students is now accepting applications for its 2026 cycle, offering $1,000 to support undergraduates pursuing healthcare careers with a focus on mental health and patient-centered care.